UCB secures €250M EU loan for CNS R&D
This article was originally published in Scrip
UCB, the Belgian pharma company, has secured long term loans worth up to €250 million from the European Investment Bank (EIB) to support R&D programmes focusing on CNS diseases. The European Union's bank has already signed over €150 million to UCB with an additional €100 million to be made available in 2013. The major indications targeted by UCB with the finance include epilepsy, Parkinson's disease, multiple sclerosis, fibromyalgia, restless leg syndrome and diabetic neuropathic pain.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.